AUTHORS
Seyed Alireza Hasheminasab, PhD, Mohammad Kazeroun, PhD2, Austeja Bakulaite, PhD3, Devi Nandana, PhD4, Hui Choo5, Maximilian Goodman6, Angela Hamblin7, Udo Oppermann8, Karthik Ramasamy, MD PhD9, Tomasz Knurowski, MD10, Mehmet Kemal Samur, PhD11, Kris Frese, PhD12, Anjan Thakurta, PhD13
AFFILIATIONS
1 University of Oxford, Oxford, United Kingdom
2 University of Oxford, Oxford, United Kingdom
3 University of Oxford, Oxford, United Kingdom
4 University of Oxford, Oxford, United Kingdom
5 University of Oxford, Oxford, United Kingdom
6 Oxford University Hospitals NHS Trust, Oxford, United Kingdom
7 Oxford University Hospitals NHS Trust, Oxford, United Kingdom
8 University of Oxford, Oxford, United Kingdom
9 University of Oxford, Oxford, United Kingdom
10 CellCentric Ltd, Cambridge, United Kingdom
11 Dana Farber Cancer Institute, Boston, United States
12 CellCentric Ltd, Cambridge, United Kingdom
13 University of Oxford, Oxford, United Kingdom
ABSTRACT
Background
Inobrodib (INO) is an investigational first-in-class oral selective p300/CBP inhibitor. INO plus pomalidomide/dexamethasone (INO-PD) is under investigation in heavily pretreated relapsed/refractory multiple myeloma (RRMM) (NCT07096778). We performed integrated genomic and transcriptomic analyses to identify molecular features associated with disease biology and response.
Methods
DNA sequencing using the MGP panel (Sudha et al, 2022, CCR) was performed on pre-treatment CD138+ cells from 86 patients. Genomics-based response analyses were performed in patients with both DNA sequencing and evaluable response, while integrated RNA/DNA analyses were restricted to 19 patients with matched RNA-seq, DNA sequencing, and clinical annotation. Differential gene expression (DGE), GSEA, and Multi-Omics Factor Analysis were performed using standard methods. Statistical significance was defined as adjusted-P<0.05, with DGE requiring |log2FC|≥1. Patients achieving ≥PR were considered responders, whereas patients with MR, SD, or progressive disease were classified as non-responders. Validation studies were performed in MM cell lines. Pre/post-treatment RNA-seq was performed across multiple doses/timepoints and viability was assessed at 96 hours. DepMap was queried to identify H3-modifier alterations.
Results
We found recurrent mutations in KRAS (23%), NRAS (15%), TP53 (15%), ATM (14%), KMT2C (12%), BRCA2 (8%), RB1 (7%), TRAF3 (6%), and ZNF292 (6%), together with high-risk (HR) features including 1q gain, del(1p), del(17p), and IGH translocations in a subset of the total 86 patients. IMWG Consensus Genomic Staging features were identified in 38/59 evaluable patients.
Exploratory responder/non-responder analyses showed response in some HR patients (e.g., 11/29 responders with del(17p)), and a positive trend in higher variant allele frequencies (VAFs) of mutations in KMT2B/C/D genes (Firth logistic regression, β = 4.98, p = 0.077; N=13). In contrast, double hit HR patients with 1q gain + t(4;14) appeared less responsive to treatment in this limited cohort. Response was observed in both pom-naïve and pom-exposed patients, but prior pomalidomide exposure was associated with reduced odds of response after adjustment for prior BCMA-targeted/T-cell engager therapy (OR 0.33, 95% CI 0.12–0.88; p=0.027), whereas prior BCMA-targeted therapy was not independently associated with response.
Among 19 samples with matched DNA/RNA sequencing, 15 were response-evaluable (10 responders, 5 non-responders). Responders were enriched for proliferative transcriptional programs including G2M checkpoint, E2F and MYC targets. In contrast, non-responders showed enrichment of interferon, TNFα/NFκB, IL6/JAK/STAT3, and unfolded protein response pathways.
In vitro, OPM2 was the most sensitive, H929 showed intermediate sensitivity, and JJN3 was the least sensitive to INO, with GI50 values of 25.68±0.60, 102.90±7.75, and 197.71±12.96 nM, respectively. Consistent with patient data, INO treatment of cells suppressed G2M, E2F, and MYC-associated transcriptional programs.
Conclusions
The targeted genomics panel showed patient profiles enriched for mutations and high-risk features consistent with late-stage multiple myeloma. However, INO-PD was active in patients with diverse genomics features suggesting a broad activity profile. Exploratory responder analysis showed highly proliferative MYC/G2M/E2F transcriptional states linked to response to INO-PD. Suppression of these pathways following INO treatment in vitro complements the potential inobrodib mechanism in patients. The association of higher KMT2B/KMT2C VAFs with response, together with greater INO sensitivity in OPM2 suggests H3K4 dysregulation may influence p300/CBP activity.
DISCLOSURES
Kris Frese, PhD: CellCentric Ltd - Current equity holder in private company; CellCentric Ltd - Current Employment